Clinical trial
Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation
NCT00248040 · Dompé Farmaceutici S.p.A, Industry · Completed
Key facts
| NCT number | NCT00248040 |
|---|---|
| Title | Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation |
| Official title | Randomized, Double-blind, Placebo-controlled, Parallel-group Pilot Study to Assess Efficacy, Safety and Pharmacokinetics of 2 Schedules of Reparixin in the Prevention of Delayed Graft Function After Kidney Transplant in High Risk Patients |
| Lead sponsor | Dompé Farmaceutici S.p.A, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ischemia-Reperfusion Injury, Kidney Diseases |
| Intervention type | Drug, Other |
| Interventions | Reparixin continuous infusion, reparixin intermittent infusion, placebo infusion |
| Enrollment | 80 |
| Start date | Oct 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Nov 3, 2005 |
| Last update posted | Jan 10, 2024 |
| Countries | France, Italy, Spain, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: